Celyad (CYAD) Stock Price, News & Analysis

Company Overview

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

Key Stats

• Today's Range: $0.40 to $0.65
• 50-Day Range: $0.59 to $0.85
• 52-Week Range: $0.46 to $3.07
• Volume: 3,009 shs
• Average Volume: N/A
• Market Capitalization: $15.91 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CYAD Stock Analysis - Frequently Asked Questions

When did Celyad IPO?

Celyad (CYAD) raised $99 million in an initial public offering on Friday, June 19th 2015. The company issued 1,400,000 shares at $70.98 per share. UBS Investment Bank and Piper Jaffray acted as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers.

What other stocks do shareholders of Celyad own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Celyad investors own include Galapagos (GLPG), Cellectis (CLLS), CRISPR Therapeutics (CRSP), Gilead Sciences (GILD), bluebird bio (BLUE), Bristol Myers Squibb (BMY) and ChromaDex (CDXC).

Company Calendar

• Today: 6/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED-BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CYAD
• CIK: 1637890
• Web: www.celyad.com
• Phone: (210) 039-4100
• Fax: 321-039-4141
• Employees: 95
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $110 thousand
• Price / Sales: 144.65
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.26 per share
• Price / Book: 2.31

Miscellaneous

• Outstanding Shares: 26,520,000
• Free Float: 26,276,000
• Market Cap: $15.91 million
• Optionable: Not Optionable
• Beta: N/A